STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model

J.M. Day, P.A. Foster, H.J. Tutill, F. Schmidlin, C.M. Sharland, J.D. Hargrave, N. Vicker, B.V.L. Potter, M.J. Reed, A. Purohit

Research output: Contribution to journalArticlepeer-review

16 Citations (SciVal)

Fingerprint

Dive into the research topics of 'STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model'. Together they form a unique fingerprint.

Medicine & Life Sciences